hackint0sh/New-Dataset huggingface dataset:
The goal of the DECIDE-T project is to reduce hospital stays and associated costs for children requiring tracheostomy/LTV, as well as to decrease mental distress and burnout experienced by their caregivers and families. conditions: Tracheostomy studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 180 type: ESTIMATED name: Digital health pathway for children with medical complexity requiring tracheostomy (DECIDE-T) measure: Hospital length of stay measure: ICU length of stay measure: ICU readmission measure: Mortality measure: Decannulation measure: Duration of tracheostomy measure: Tracheostomy adverse events measure: Hospital cost measure: Hospital readmission measure: Net-monetary benefit of DECIDE-T measure: Caregivers mental stress sex: ALL maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Alberta Children's Hospital city: Calgary state: Alberta country: Canada name: Karen Kam, MD role: CONTACT email: karen.kam@albertahealthservices.ca name: Karen Kam, MD role: PRINCIPAL_INVESTIGATOR lat: 51.05011 lon: -114.08529 facility: Stollery Children's Hospital city: Edmonton state: Alberta country: Canada name: Michael van Manen, MD role: CONTACT email: michaelv@ualberta.ca name: Michael van Manen, MD role: PRINCIPAL_INVESTIGATOR lat: 53.55014 lon: -113.46871 hasResults: False
nctId: NCT06375356 id: 75119 briefTitle: Stronger: Muscle Strengthening for Menopause overallStatus: NOT_YET_RECRUITING date: 2024-08 date: 2026-08 date: 2026-08 date: 2024-04-19 date: 2024-04-19 name: Stanford University class: OTHER briefSummary: Menopause is a period of time with increased risk for muscle and bone loss. Very few people strength train regularly at least 2 times per week, and commonly reported barriers include inadequate time and resources, worries of safety, inadequate knowledge base of what moves to do and how to do them. Menopause-aged women may report unique barriers - or perceived facilitators - to strength training. This pilot study will develop and test the feasibility and acceptability of an at-home, band-based, expert-supported strength training intervention. conditions: Resistance Training studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 60 type: ESTIMATED name: Resistance Training measure: number of strength exercises the participant logged over the intervention measure: Liking of the intervention measure: Number of participants completing post 3 month measure / those randomized and consented measure: Change in total seconds a participant can remain in a wall sit measure: Change in number of full body weight squats in 60 seconds sex: FEMALE minimumAge: 35 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Stanford University School of Medicine city: Stanford state: California zip: 94305-7240 country: United States lat: 37.42411 lon: -122.16608 hasResults: False
nctId: NCT06375343 id: SOPH240-0923/I briefTitle: Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive® overallStatus: NOT_YET_RECRUITING date: 2024-10-30 date: 2024-10-30 date: 2025-06 date: 2024-04-19 date: 2024-04-19 name: Laboratorios Sophia S.A de C.V. class: INDUSTRY briefSummary: This is a phase I clinical study to evaluating safety and tolerability of PRO-240 ophthalmic solution through the incidence of unexpected adverse events, as well as through changes in Best Corrected Visual Acuity (BCVA), and the incidence of stinging after its administration, compared to Optive®. conditions: Dry Eye Disease conditions: Dry Eye Sensation conditions: Ocular Surface Disease studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Phase I, controlled, comparative, single-blind, single-center, comparative clinical trial. primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 32 type: ESTIMATED name: PRO-240 name: Optive® measure: Incidence of unexpected adverse events related to the interventions measure: Changes in the Ocular Comfort Index score measure: Adherence to treatment (adherence) Adherence to treatment (adherence) measure: Changes in Best Corrected Visual Acuity (BCVA) measure: Changes in tear film breakup time measure: Changes in intraocular pressure (IOP) measure: Changes in the integrity of the ocular surface (fluorescein staining) measure: Changes in lissamine green staining of the conjunctival surface sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06375330 id: Poli.01 briefTitle: Clinical Efficacy of Polynucleotides TMJ Injections Compared to Physiotherapy. overallStatus: COMPLETED date: 2023-04-18 date: 2024-01-08 date: 2024-04-08 date: 2024-04-19 date: 2024-04-19 name: Sidoti & Tartaglia Srl class: OTHER briefSummary: The main objective of the present study is the evaluation of the clinical efficacy of the intra-articular administration of polynucleotides in association with hyaluronic acid in the improvement of the subjective and objective manifestations of arthrosis of the temporomandibular joint compared to normal clinical management which involves Physiotherapy. conditions: TMJ Disease conditions: TMJ Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 60 type: ACTUAL name: PoliArt measure: Maximum mouth opening measure: Lateral movements improvements measure: Pain assessment sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: UOC di Chirurgia Maxillo-Facciale e Odontostomatologia della Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico city: Milan state: MI zip: 20122 country: Italy lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06375317 id: HCC-HAIC-001 briefTitle: HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2026-04-30 date: 2026-10-30 date: 2024-04-19 date: 2024-04-19 name: Yehua Shen class: OTHER briefSummary: For patients with advanced liver cancer who have progressed after first-line targeted and immunotherapy , there is currently no standard treatment regimen for second-line therapy. this study aims to explore the efficacy and safety of HAIC combined with PD-L1 and Regorafenib in patients with advanced liver cancer who have failed immunotherapy, not only providing new treatment options for second-line therapy of liver cancer, but also laying the foundation for research on the combination of HAIC and PD-L1 inhibitors plus Regorafenib, which has significant scientific research significance and clinical value. conditions: HCC - Hepatocellular Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 42 type: ESTIMATED name: PD-L1 inhibitor: Adebrelimab Injection；Regorafenib Tablets measure: Objective Response Rate measure: Disease Control Rate (DCR) measure: Progression-Free Survival (PFS) measure: Overall Survival (OS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06375304 id: MP-37-2024-10384 briefTitle: The Antiretroviral Speed Access Program Switch (ASAP-Switch) Study overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-06-01 date: 2027-05-01 date: 2024-04-19 date: 2024-04-19 name: McGill University Health Centre/Research Institute of the McGill University Health Centre class: OTHER briefSummary: This project builds on our experience with the ASAP Study (McGill University Health Centre research ethics board: MP-37-2020-4911). The goal of this study is to better understand the experience of migrant people with Human Immunodeficiency Virus (HIV) of having their treatment switched to Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF). In other words, the investigators want to evaluate how feasible and acceptable this switch is, and how participants will take B/F/TAF (fidelity) and remain on it. The investigators also want to know more about migrant people with HIV's experience of care; namely, how often they see their HIV specialist or other healthcare professionals, and their healthcare coverage (the type of insurance that they have). conditions: HIV Infections studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 50 type: ESTIMATED name: B/F/TAF measure: Feasibility of the switch measure: Acceptability measure: acceptability of the regimen measure: Acceptability of the intervention measure: Fidelity measure: ART initiation (HIV care cascade milestones) measure: Viral suppression (HIV care cascade milestones) measure: Retention in HIV care (HIV care cascade milestones) measure: consultations at the study site (Nature of clinical pathways) measure: consultations at other care centres or organizations (Nature of clinical pathways) measure: healthcare coverage sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Research Institute of the McGill University Health Centre city: Montréal state: Quebec zip: H4A3T2 country: Canada name: Bertrand Lebouché, MD, PhD role: CONTACT phone: +1-514-843-2090 email: bertrand.lebouche@mcgill.ca name: Ashkan Baradaran, MD, MSc role: CONTACT phone: +1 514-863-4468 email: ashkan.baradaran@muhc.mcgill.ca lat: 45.50884 lon: -73.58781 hasResults: False
nctId: NCT06375291 id: MersinTRHpregcts briefTitle: Pregnancy-Related Carpal Tunnel Syndrome Treatment overallStatus: COMPLETED date: 2021-01-01 date: 2023-12-31 date: 2024-03-31 date: 2024-04-19 date: 2024-04-22 name: Mersin Training and Research Hospital class: OTHER_GOV briefSummary: The current retrospective study aimed to compare the effectiveness of local steroid injection plus splinting with that of local steroid injection or splinting alone. To assess the primary outcome, The Boston Carpal Tunnel Symptom Severity Scale was used. The secondary aim was the efficacy of the treatment on the patient's function severity and depression assessed by The Boston Carpal Tunnel Symptom Function Scale Edinburgh Depression Scale. conditions: Carpal Tunnel Syndrome Pregnancy studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 45 type: ACTUAL name: splint /steroid injection/both measure: Symptom severity measure: function severity measure: pregnancy and postpartum depression sex: FEMALE minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT facility: Suna Aşkın Turan city: Mersin state: Yenişehir zip: 33020 country: Turkey lat: 36.79526 lon: 34.61792 hasResults: False
nctId: NCT06375278 id: DC019586 id: 5R44DC019586 type: NIH link: https://reporter.nih.gov/quickSearch/5R44DC019586 briefTitle: Investigation of a Device to Deliver Intra-Operative Therapeutic Hypothermia for Hearing Preservation in Cochlear Implantation overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-12-31 date: 2026-03-31 date: 2024-04-19 date: 2024-04-19 name: Restorear Devices LLC class: INDUSTRY name: University of Miami name: National Institute on Deafness and Other Communication Disorders (NIDCD) briefSummary: The goal of this interventional clinical study is to investigate the use of mild therapeutic hypothermia for preservation of residual hearing in cochlear implant surgery. The main questions the trial aims to answer are:
Participants will receive mild therapeutic hypothermia therapy during cochlear implant surgery. Researchers will compare results from those receiving the therapy to those from a control group (individuals receiving no therapy). conditions: Cochlear Implants conditions: Cochlear Implantation conditions: Hearing Loss studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 54 type: ESTIMATED name: Intra-Ear Canal Cooling Catheter name: Intra-Ear Canal Cooling Catheter (Sham) measure: Cochlear Implant (CI) Device Performance Following Hypothermia Treatment measure: Residual Hearing measure: Electrophysiological Impedance measure: Electrically Evoked Compound Action Potential (ECAP) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Miami city: Miami state: Florida zip: 33136 country: United States lat: 25.77427 lon: -80.19366 hasResults: False
nctId: NCT06375265 id: 2024P000780-1 briefTitle: Digital Sleep Optimization for Brain Health Outcomes in Older Surgical Patients acronym: SLEEP-BOOST overallStatus: NOT_YET_RECRUITING date: 2024-10-31 date: 2026-05-31 date: 2026-08-31 date: 2024-04-19 date: 2024-04-19 name: Massachusetts General Hospital class: OTHER briefSummary: The Sleep Optimization for Brain Health Outcomes in Older Surgical Patients (SLEEP-BOOST) is a pilot randomized, controlled, singled-blinded (participant) trial in major orthopedic joint surgery patients that will build on a previously clinically tested cognitive behavioral therapy for insomnia (CBT-I) mobile application paired with a wearable device (wrist actigraphy). conditions: Insomnia conditions: Postoperative Delirium conditions: Delayed Neurocognitive Recovery conditions: Postoperative Neurocognitive Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 50 type: ESTIMATED name: digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) name: Sleep Health Education measure: Adherence measure: Insomnia Severity measure: Sleep Diary Completion measure: Homework Completion measure: Utility measure: Satisfaction with intervention measure: Cognition measure: Pain severity measure: Mood measure: Anxiety measure: Function measure: Postoperative Delirium Incidence measure: Postoperative Delirium Severity measure: Delayed Neurocognitive Recovery measure: Postoperative Neurocognitive Disorders (NCD) measure: Sleep Efficiency measure: Circadian Rest-Activity Rhythms sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: Massachusetts General Hospital city: Boston state: Massachusetts zip: 02114 country: United States lat: 42.35843 lon: -71.05977 hasResults: False
nctId: NCT06375252 id: sbughfyaseminozkan1985 briefTitle: Evaluation of Central Jugular Vein Catheter Lumen Holder Design and Ergonomic Use acronym: CJVClumen overallStatus: NOT_YET_RECRUITING date: 2024-04-19 date: 2024-05-16 date: 2024-05-30 date: 2024-04-19 date: 2024-04-19 name: Saglik Bilimleri Universitesi class: OTHER briefSummary: The aim of this study was to evaluate the design and ergonomic use of central jugular vein catheter lumen holder. conditions: Central Venous Catheterization studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 40 type: ESTIMATED name: Central Jugular Vein Catheter Lumen Holder Apparatus measure: demographic information measure: comfort effect sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06375239 id: RTx-VRAI-NHS01 briefTitle: Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Retinitis Pigmentosa Patients overallStatus: RECRUITING date: 2024-04-05 date: 2026-04-30 date: 2026-04-30 date: 2024-04-19 date: 2024-04-19 name: Ray Therapeutics, Inc. class: INDUSTRY name: The Vision Research and Assessment Institute (VRAI) briefSummary: RayTx established The Vision Research and Assessment Institute (VRAI) with the express purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision. The mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment to be performed by expert clinicians in an optimized environment. The proposed assessments or testing modalities to be evaluated in this non-interventional study are published in some capacity, and some of these publications already include patients with severe-to-profound vision loss from retinitis pigmentosa and other inherited retinal diseases. conditions: Retinitis Pigmentosa studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 40 type: ESTIMATED measure: Operational feasibility of testing severe to profound vision impaired patients with RP on a battery of visual assessments measure: To quantify patient-based measurement properties of each test modality (for the purposes of endpoint qualification) measure: To quantify assessor-based measurement properties of each test modality (for the purposes of endpoint qualification) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Vision Research and Assessment Institute status: RECRUITING city: Irvine state: California zip: 92612 country: United States name: Shawn Yu, OD role: CONTACT phone: 949-264-3793 email: info@vr-ai.com lat: 33.66946 lon: -117.82311 hasResults: False
nctId: NCT06375226 id: 2023.17 id: 2023.0871 type: OTHER domain: METC Amsterdam UMC briefTitle: Autism and Attachment. An Explorative Study of Attachment Styles in Autistic Adults. acronym: ASDA overallStatus: RECRUITING date: 2024-03-01 date: 2025-04-01 date: 2025-04-01 date: 2024-04-19 date: 2024-04-23 name: Parnassia Groep class: OTHER briefSummary: The present study examines the relationship between attachment and autism spectrum disorder (ASD) in adults. conditions: Autism Spectrum Disorder studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 60 type: ESTIMATED measure: The Social Responsiveness Scale - Adult version (SRS-A) measure: The Attachment Styles Questionnaire (ASQ) measure: Experiences in Close Relationships - Revised questionnaire (ECR-r) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: ParnassiaGroep Antes status: RECRUITING city: Rotterdam state: Zuid-Holland zip: 3083 AK country: Netherlands name: Stephanie Bohnen, MSc role: CONTACT phone: +31653386139 email: s.bohnen@anteszorg.nl name: Richard Vuijk, Dr. role: CONTACT phone: +31883585428 email: r.vuijk@anteszorg.nl lat: 51.9225 lon: 4.47917 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-10-19 uploadDate: 2024-03-29T08:28 filename: Prot_SAP_000.pdf size: 287252 hasResults: False
nctId: NCT06375213 id: 425/66 briefTitle: Investigating Neurocognitive Disorders Epidemiology acronym: INDE overallStatus: RECRUITING date: 2023-08-24 date: 2035-08-24 date: 2035-08-24 date: 2024-04-19 date: 2024-04-22 name: King Chulalongkorn Memorial Hospital class: OTHER name: Health Systems Research Institute,Thailand briefSummary: This is a prospective cohort study with the main purpose of predicting progression neurocognitive disorders in Thai population. The main predictor variables to be evaluated are plasma phosphorylated tau (p-tau) level and cognitive test scores, which will be combined using statistical/computational modeling. Additionally, it seeks to evaluate biomarkers for diagnosing disease pathologies, understand their correlation with clinical outcomes, and explore the socioeconomic impact of neurocognitive disorders. The study invites both participants for biospecimen collection, structured interviews, and cognitive examinations and schedules follow-up visits annually or biennially. conditions: Dementia conditions: Cognitive Decline conditions: Alzheimer Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 990 type: ESTIMATED name: Plasma tau phosphorylated at Thr217 name: Neurocognitive examination measure: Progression to dementia measure: Changes in Sum of Boxes of the Clinical Dementia Rating Scale measure: Changes in the Montreal Cognitive Assessment measure: Changes in the Montreal Cognitive Assessment - Memory Index Score measure: Changes in the Mini Mental State Examination measure: Changes in the Wechsler Memory Scale - Fourth Edition (WMS-IV) Visual Reproduction Scaled Score measure: Changes in the Wechsler Memory Scale - Fourth Edition (WMS-IV) Logical Memory Scaled Score measure: Changes in the Wechsler Memory Scale - Fourth Edition (WMS-IV) Verbal Paired Associates Scaled Score measure: Biological diagnosis of Alzheimer's disease measure: Biological staging of Alzheimer's disease measure: Quantitative amyloid PET uptake. measure: Quantitative tau PET uptake in various cortical regions. measure: Future diagnosis of Alzheimer's disease dementia. measure: Quality of life (WHOQOL-BREF) measure: Quality of life (EQ-5D-5L) measure: Number of modifiable risk factors sex: ALL minimumAge: 35 Years stdAges: ADULT stdAges: OLDER_ADULT facility: King Chulalongkorn Memorial Hospital status: RECRUITING city: Pathum Wan state: Bangkok zip: 10330 country: Thailand name: Adipa Chongsuksantikul, D.Eng. role: CONTACT phone: +66 (0)84 1134443 email: adipar@gmail.com lat: 13.73649 lon: 100.5239 hasResults: False
nctId: NCT06375200 id: ONZ-2024-0066 briefTitle: Healthcare for Men With Suicidal Thoughts: Needs Assessment acronym: KUJK2NEEDS overallStatus: RECRUITING date: 2024-04-25 date: 2024-07-01 date: 2024-10-10 date: 2024-04-19 date: 2024-04-29 name: University Ghent class: OTHER briefSummary: The aim of the current project is twofold, namely
2. What needs and barriers do health care providers experience when working with men (in comparison to women or people of other genders) who are feeling suicidal? conditions: Suicide Prevention conditions: Help-Seeking Behavior conditions: Men studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 586 type: ESTIMATED measure: STUDY 1: Help-seeking behavior measure: STUDY 1: Experienced need measure: STUDY 1: Emotional Openness measure: STUDY 1: Barriers measure: STUDY 1: Self-reliance measure: STUDY 1: Stigma measure: STUDY 1: needs of individuals with suicidal ideation measure: STUDY 2: needs of healthcare providers measure: STUDY 1: Socio-demographic characteristics measure: STUDY 1: Suicidality measure: STUDY 2: socio-demographic variables measure: STUDY 2: Professional experience with men with suicidal thoughts sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Flemish Centre of Expertise in Suicide Prevention, Ghent University status: RECRUITING city: Ghent zip: 9000 country: Belgium name: Eva De Jaegere, MSc role: CONTACT phone: +3293320775 email: eva.dejaegere@ugent.be lat: 51.05 lon: 3.71667 hasResults: False
nctId: NCT06375187 id: GC203 TIL-ST-Ⅰ briefTitle: Engineering Tumor Infiltrating Lymphocytes Injection (GC203 TIL) for the Treatment of Advanced Malignant Solid Tumors acronym: KUNLUN-001 overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-11-01 date: 2027-05-01 date: 2024-04-19 date: 2024-04-23 name: Shanghai Juncell Therapeutics class: INDUSTRY briefSummary: A clinical trial to assess the safety and efficacy of engineered Tumor Infiltrating Lymphocytes (TIL) for the treatment of Advanced Malignant Solid Tumors conditions: Solid Tumor conditions: Gynecologic Cancer conditions: Breast Cancer conditions: Gastrointestinal Cancer conditions: Lung Cancer studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 18 type: ESTIMATED name: Engineering Tumor Infiltrating Lymphocytes measure: Maximal Tolerance Dose measure: Dose Limiting Toxicity measure: Adverse Events measure: Objective Response Rate measure: Duration of Response measure: Disease Control Rate measure: Progression-Free Survival measure: Overall Survival measure: Quality of Life Assessment sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False